

#15
Dmt
10-28-03

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : Richard C. Deth
 Application No. : 09/550,103
 Filed : April 14, 2000
 Confirmation No. : 8235
 For : METHODS OF IDENTIFYING AND DETERMINING THE
 EFFECTIVENESS OF THERAPEUTIC PROCESSES OR
 AGENTS FOR THE DIAGNOSIS AND TREATMENT OF
 SCHIZOPHRENIA AND RELATED DISORDERS
 Examiner : Sandra Wegert
 Attorney's Docket : NU-431AX

TC Art Unit: 1647

 I hereby certify that this correspondence is being sent via
 facsimile to Examiner Sandra L. Wegert, TC Art Unit 1647, Fax No.
 (703) 308-4242, on Oct. 23, 2003.

By:

Holliday C. Heine
 Holliday C. Heine, Ph.D.
 Registration No. 34,346
 Attorney for Applicant(s).

DECLARATION OF RICHARD C. DETH, PH.D.
UNDER 37 C.F.R. §1.132

Via Facsimile
 After Final
 Commissioner for Patents
 Washington, D.C. 20231

RECEIVED
 CENTRAL FAX CENTER

OCT 23 2003

OFFICIAL

I, Richard C. Deth, Ph.D., a citizen of the United States of
 America, residing at 1484 Beacon Street, Waban, Massachusetts
 02468, declare the following:

1. I received my doctoral degree in Pharmacology from the
 University of Miami (Florida) in 1975. I am currently a Professor
 of Pharmacology at Northeastern University in Boston,
 Massachusetts.

WEINGARTEN, SCHURGIN,
 CAGNESIN & LEBOVICI LLP
 TEL. (617) 542-2200

Application No. 09/550,103

Filed: April 14, 2000

TC Art Unit: 1647

Confirmation No.: 8235

2. I specialize in the study of signaling pathways involving G protein-coupled receptors such as the D₄ dopamine receptor. My particular interest is focused on folate-dependent methylation reactions, their control by dopamine and growth factors, and their involvement in various mental illnesses.

3. I am an inventor of the subject matter set forth in the present, above-identified patent application.

4. I have read and am familiar with the prosecution history of the present application, including the Office Action dated May 20, 2003 (Paper No. 12).

5. The detailed action of the Office Action rejects claims 5-9 under 35 U.S.C. §112, first paragraph, because "the Specification, while being enabling for a method identifying therapeutic agents for neuropsychiatric diseases involving the D₄ receptor and in which phospholipid methylation has been shown to be affected, does not reasonably provide enablement for agents or processes involving other neuropsychiatric diseases in which a clear link from the D₄ receptor to phospholipid methylation has not been established."

6. This declaration provides support that the specification is enabling for methods of identifying agents or processes for treating neuropsychiatric disorders, in addition to schizophrenia, in which there is a link from the dopamine D₄ receptor to phospholipid methylation. Specifically, given the theory behind the methods of the invention as proposed by the Applicant and described in the specification and given the state of general

Application No. 09/550,103
Filed: April 14, 2000
TC Art Unit: 1647
Confirmation No.: 8235

knowledge at the time the instant application was filed concerning the likely causes of other neuropsychiatric diseases related to schizophrenia, those of ordinary skill in the art would have believed that the Applicant's experimental showings with respect to schizophrenia were directly relatable to other neuropsychiatric diseases. Herein below are descriptions of exemplary neuropsychiatric disorders or diseases involving changes in D₄ receptor-linked phospholipid methylation.

7. An exemplary neuropsychiatric disorder is autism. From what was known about the causes of autism at the time this application was filed, it is my opinion that one of ordinary skill in the art would accept my assertion that the methods of the invention would be useful in identifying agents or processes for treating autism. Autism can be caused by genetic mutations (such as those impairing the adenosylsuccinate lyase enzyme in the purine synthesis pathway^{1,2}) that result in the diversion of single-carbon groups away from the folate pathway. As I have now shown, this type of diversion results in a deficit in the availability of 5-methyl tetrahydrofolate for folate-dependent methylation of the dopamine D₄ receptor and subsequent D₄ receptor-mediated phospholipid methylation. Thus, it would be considered credible by those of ordinary skill that detection of a change in the level of dopamine D₄ receptor-mediated phospholipid methylation could be used as an assay system for candidate agents for the treatment of autism, as claimed in the instant application.

8. Adenosylsuccinate lyase mutations, as discussed above, cause preferential diversion of single-carbon groups from the

Application No. 09/550,103

Filed: April 14, 2000

TC Art Unit: 1647

Confirmation No.: 8235

folate pathway to purine synthesis. It is known that another developmental disorder, Lesch-Nyhan syndrome is also associated with excessive activity of the purine synthesis pathway³. Additional developmental disorders, including Fragile-X syndrome⁴ and Angelman and Prader-Willi Syndromes⁴, involve abnormal DNA methylation and gene silencing. Thus, developmental disorders as a group appear to involve abnormal folate-dependent methylation events, linking them to folate-dependent D₄ receptor-linked phospholipid methylation and to use of the assay system according to the invention as a screening tool for candidate therapeutic agents.

9. One of the hallmark symptoms of autism is impaired attention. This includes attention to other persons as well as impairment of attention-related learning⁵. This symptom is also common in schizophrenia⁶ and, of course, attention-deficit hyperactivity disorder (ADHD). D₄ dopamine receptors have been linked to the risk of ADHD⁷ and ADHD is widely recognized as a disorder of dopamine signaling⁸, so diseases in which there is a deficit of attention are likely to be related to D₄ receptor-mediated phospholipid methylation. Thus, attention-deficit hyperactivity disorder can be considered as being a "schizophrenia-related disorder," since both disorders appear to include an important role for D₄ dopamine receptor-mediated phospholipid methylation.

10. Alzheimer's disease is associated with reduced levels of vitamin B-12^{9,10}, the required co-factor for methionine synthase that brings methyl groups from the folate pathway to the D₄ dopamine receptor. Treatment with 5-methyl tetrahydrofolate, the

Application No. 09/550,103

Filed: April 14, 2000

TC Art Unit: 1647

Confirmation No.: 8235

source of methyl groups for the D₄ receptor phospholipid methylation process, has been shown to improve dementia¹¹. Levels of S-adenosylmethionine, a methyl donor, are lower in Alzheimer's disease¹². Furthermore, the enzyme activity of methionine adenosyltransferase, required in the cycle of D₄ dopamine receptor-mediated phospholipid methylation, is reduced in Alzheimer's disease¹³. Thus, there is considerable evidence for impairments that involve D₄ receptor-mediated phospholipid methylation in Alzheimer's disease, such that it should also be considered as a "related neuropsychiatric disorder" in the context of the screening methods of the invention as claimed in the instant application.

11. Based on the foregoing and what is generally known in the art, those of ordinary skill would believe from what I have disclosed in the instant application that there is a sufficient correlation between changes in D₄ receptor-linked phospholipid methylation and other neuropsychiatric disorders related to schizophrenia that the screening methods claimed therein would be likely to generate candidate therapeutic agents or processes for these related disorders. The state of the art at the time of filing, when read with the knowledge of my results, indicates to those of ordinary skill that neuropsychiatric disorders related to schizophrenia, in general, involve changes in dopamine D₄ receptor-linked phospholipid methylation.

Application No. 09/550,103

Filed: April 14, 2000

TC Art Unit: 1647

Confirmation No.: 8235

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements so made may jeopardize the validity of the document, or application, or any patent issuing thereon.

Signed this 30th day of September, 2003.

By:

Richard C. Deth
Richard C. Deth, Ph.D.

Enclosure: List of Cited References (Attached hereto)

RECEIVED
CENTRAL FAX CENTER

OCT 23 2003

OFFICIAL

Application No. 09/550,103

Filed: April 14, 2000

TC Art Unit: 1647

Confirmation No.: 8235

Cited References

1. Jaeken J, Van den Bergh G. An infantile autistic syndrome characterised by the presence of succinylpurines in body fluids. Lancet. 1984 Nov 10;2(8411):1058-61.
2. Stone RL, Aimi J, Barshop BA, Jaeken J, Van den Berghe G, Zalkin H, Dixon JE. A mutation in adenylosuccinate lyase associated with mental retardation and autistic features. Nat Genet. 1992 Apr;1(1):59-63.
3. Allsop J, Watts RW. Purine syntesis de novo and salvage in hypoxanthine phosphoribosyltransferase-deficient mice. Enzyme. 1990;43(3):155-9.
4. Arrieta I, Nunez T, Gil A, Flores P, Usobiaga E, Martinez B. Autosomal folate sensitive fragile sites in an autistic Basque sample. Ann Genet. 1996;39(2):69-74.
5. Eppright TD, Sanfacon JA, Horwitz EA. Attention deficit hyperactivity disorder infantile autism, and elevated blood-lead: a possible relationship. Mol. Med. 1996 Mar;93(3):136-8.
6. Sereno AB, Holzman PS. Spatial selective attention in schizophrenic, affective disorder, and normal subjects. Schizophr Res. 1996 May;20(1-2):33-50.
7. LaHoste GJ, Swanson JM, Wigal SB, Glabe C, Wigal T, King N, Kennedy JL. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry. 1996 May;1(2):121-4.
8. Pliszka SR, McCracken JT, Maas JW. Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry. 1996 Mar;35(3):264-272.
9. Abalan F, Delile JM. B12 deficiency in presenile dementia. Biol Psychiatry. 1985 Nov;20(11):1251
10. Cole MG, Prchal JF. Low serum vitamin B12 in Alzheimer-type dementia. Age Ageing. 1984 Mar;13(2):101-5.
11. Passeri M, Cucinotta D, Abate G, Senin U, Ventura A, Stramba Badiale M, Diana R, La Greca P, Le Grazie C. Oral 5'-

Application No. 09/550,103
Filed: April 14, 2000
TC Art Unit: 1647
Confirmation No.: 8235

methylnetetrahydrofolic acid in senile organic mental disorders with depression: results of a double-blind multicenter study. Aging (Milano). 1993 Feb;5(1):63-71.

12. Bottiglieri T, Hyland K. S-adenosylmethionine levels in psychiatric and neurological disorders: a review. Acta Neurol Scand Suppl. 1994;154:19-26.

13. Gomes Trolin C, Regland B, Oreland L. Decreased methionine adenosyltransferase activity in erythrocytes of patients with dementia disorders. Eur Neuropsychopharmacol. 1995 Jun;5(2):107-14.

287044-2